A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy
Public ClinicalTrials.gov record NCT01399580. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Prospective, Randomized, Double-Blind, Parallel Design, Placebo-Controlled Multicenter Study. The study objectives are to evaluate efficacy and safety, including thoracic bioimpedance, of once daily administration of atrasentan tablets (high dose and low dose) compared to placebo in type 2 diabetic subjects with nephropathy who are receiving the maximum tolerated labeled daily dose of a RAS inhibitor.
Study identification
- NCT ID
- NCT01399580
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 48 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2011 (Type not available)
- Primary completion
- Sep 2012 (Actual)
- Completion
- Sep 2012 (Actual)
- Last update posted
- Oct 25, 2013
2011 – 2012
United States locations
- U.S. sites
- 28
- U.S. states
- 15
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Reference ID/Investigator# 58144 | Phoenix | Arizona | 85032 | — |
| Site Reference ID/Investigator# 71034 | Tempe | Arizona | 85284 | — |
| Site Reference ID/Investigator# 56927 | Azusa | California | 91702 | — |
| Site Reference ID/Investigator# 70793 | Azusa | California | 91702 | — |
| Site Reference ID/Investigator# 64027 | Chula Vista | California | 91910 | — |
| Site Reference ID/Investigator# 54120 | Concord | California | 94520 | — |
| Site Reference ID/Investigator# 64026 | La Mesa | California | 91942 | — |
| Site Reference ID/Investigator# 70173 | Los Angeles | California | 90048 | — |
| Site Reference ID/Investigator# 54121 | Denver | Colorado | 80209 | — |
| Site Reference ID/Investigator# 56924 | Boynton Beach | Florida | 33472 | — |
| Site Reference ID/Investigator# 56642 | Hollywood | Florida | 33021 | — |
| Site Reference ID/Investigator# 68986 | Augusta | Georgia | 30901 | — |
| Site Reference ID/Investigator# 56644 | Chicago | Illinois | 60611 | — |
| Site Reference ID/Investigator# 54129 | Baton Rouge | Louisiana | 70808 | — |
| Site Reference ID/Investigator# 68982 | Pontiac | Michigan | 48341 | — |
| Site Reference ID/Investigator# 64023 | Albany | New York | 12206 | — |
| Site Reference ID/Investigator# 55543 | Flushing | New York | 11355 | — |
| Site Reference ID/Investigator# 54164 | Fargo | North Dakota | 58103 | — |
| Site Reference ID/Investigator# 58147 | Willoughby Hills | Ohio | 44094 | — |
| Site Reference ID/Investigator# 54123 | Bethlehem | Pennsylvania | 18017 | — |
| Site Reference ID/Investigator# 61742 | Pittsburgh | Pennsylvania | 15224 | — |
| Site Reference ID/Investigator# 54132 | Chattanooga | Tennessee | 37408 | — |
| Site Reference ID/Investigator# 54108 | Dallas | Texas | 75231 | — |
| Site Reference ID/Investigator# 54126 | Greenville | Texas | 75402 | — |
| Site Reference ID/Investigator# 58153 | Houston | Texas | 77024 | — |
| Site Reference ID/Investigator# 54110 | Houston | Texas | 77099 | — |
| Site Reference ID/Investigator# 54116 | North Richland Hills | Texas | 76180 | — |
| Site Reference ID/Investigator# 54173 | Silverdale | Washington | 98383 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01399580, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 25, 2013 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01399580 live on ClinicalTrials.gov.